Impact of abiraterone acetate with and without prior docetaxel chemotherapy on the survival of patients with metastatic castration-resistant prostate cancer: a population-based study

BACKGROUND: Abiraterone acetate was introduced in Quebec in 2012 for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who had received chemotherapy with docetaxel. This study describes abiraterone use in the early postapproval period and its clinical effectiveness...

詳細記述

保存先:
書誌詳細
出版年:CMAJ Open
主要な著者: Rocha, Joice, Aprikian, Armen G., Vanhuyse, Marie, Cury, Fabio L., Hu, Jason, Prévost, Noémie, Dragomir, Alice
フォーマット: Artigo
言語:Inglês
出版事項: Joule Inc. or its licensors 2017
主題:
Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5378527/
https://ncbi.nlm.nih.gov/pubmed/28401143
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.9778/cmajo.20160082
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料